Advertisement
Advertisement
U.S. markets close in 1 hour 48 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Incyte Corporation (INCY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
74.29+0.90 (+1.23%)
As of 02:12PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close73.39
Open73.34
Bid74.19 x 900
Ask74.21 x 900
Day's Range72.49 - 74.82
52 Week Range61.91 - 88.26
Volume701,334
Avg. Volume1,453,719
Market Cap16.456B
Beta (5Y Monthly)0.72
PE Ratio (TTM)17.40
EPS (TTM)4.27
Earnings DateAug 01, 2022 - Aug 05, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est92.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
62% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for INCY

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Incyte Corporation
    Analyst Report: Incyte CorporationIncyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
    Rating
    Fair Value
    Economic Moat
    16 days agoMorningstar
View more
  • Motley Fool

    2 Under-the-Radar Biotech Stocks to Buy in 2022

    With that as a backdrop, let's consider two biotech stocks that don't grab a lot of headlines but deserve serious consideration: Incyte (NASDAQ: INCY) and Axsome Therapeutics (NASDAQ: AXSM). Incyte is a drugmaker with a particular focus on the field of oncology. Its best-selling product is called Jakafi, which treats some types of bone marrow cancer, among other conditions.

  • Benzinga

    Mizuho Sees Relief For This Small-Cap Stock After Patent Legal Overhang Lifted

    The US Patent Trial and Appeal Board (PTAB) issued a final written decision in favor of Concert Pharmaceuticals Inc (NASDAQ: CNCE) regarding the post-grant review (PGR) for the '659 method-of-use patent. The '659 patent claims methods of treating hair loss, including alopecia areata with certain doses of CTP-543, a deuterated form of ruxolitinib, JAK 1/2 inhibitor, being marketed by Incyte Corporation (NASDAQ: INCY). The patent expires in 2037. PTAB upholds all of the challenged claims of the '6

  • Motley Fool

    Why CTI Biopharma Stock Is Surging Today

    Shares of CTI BioPharma (NASDAQ: CTIC) moved sharply higher after the drugmaker reported first-quarter results Friday morning. Investors were pleased with the initial sales figures for Vonjo, its first approved drug, and pushed the stock price 20.8% higher as of 11:22 a.m. ET. On March 1, 2022, the FDA approved Vonjo to treat patients with myelofibrosis, a rare bone marrow disorder.

Advertisement
Advertisement